Cronos Group (TSE:CRON) Trading Up 1.6% – Still a Buy?

Cronos Group Inc. (TSE:CRON)’s share price was up 1.6% on Tuesday . The company traded as high as C$3.85 and last traded at C$3.81. Approximately 88,037 shares were traded during mid-day trading, a decline of 50% from the average session volume of 177,427 shares. The stock had previously closed at C$3.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CRON shares. TD boosted their price target on shares of Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. TD Securities set a C$4.50 price objective on Cronos Group and gave the company a “buy” rating in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of C$4.75.

Cronos Group Price Performance

The stock has a market cap of C$1.42 billion, a price-to-earnings ratio of -188.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.13. The company has a 50-day simple moving average of C$3.73 and a two-hundred day simple moving average of C$3.67. The company has a debt-to-equity ratio of 0.12, a quick ratio of 24.01 and a current ratio of 21.87.

Cronos Group (TSE:CRON) last announced its quarterly earnings data on Monday, May 11th. The company reported C$0.06 earnings per share (EPS) for the quarter. The company had revenue of C$62.86 million for the quarter. Cronos Group had a negative return on equity of 0.19% and a negative net margin of 1.29%. As a group, equities research analysts forecast that Cronos Group Inc. will post -0.26 EPS for the current year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.